Connect your AI

Pacira BioSciences, Inc. PCRX Change in AR

Change in AR at other companies

Avanos MedicalAVNS

$300K+101%

Collegium Pharmaceutical, Inc.COLL

$17.43M+10,155%

AtriCureATRC

$5.02M+86.9%

Other financials

Income statement

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

Market cap$942.78M-16.0%

Enterprise value$1.21B+1.2%

P/E183.5×—

P/S1.3×-0.3×

Profitability

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pacira BioSciences, Inc.'s change in AR?: Pacira BioSciences, Inc. (PCRX) reported change in AR of $1.57M in Q1 2026.
How has Pacira BioSciences, Inc.'s change in AR changed year-over-year?: Pacira BioSciences, Inc.'s change in AR increased by 118.3% year-over-year, from -$8.56M to $1.57M.
What is the long-term trend for Pacira BioSciences, Inc.'s change in AR?: Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s change in AR has grown at a 0.7% compound annual growth rate (CAGR), from $10.43M to $10.74M.
What does change in AR mean?: Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.